Related Experiment Videos
Insights
Ontario's newborn screening program for phenylketonuria (PKU) successfully identified and treated infants. Early detection and care for PKU significantly reduced the incidence of intellectual disability and associated costs.
Area of Science:
- Medical screening programs
- Pediatric metabolic disorders
- Public health initiatives
Background:
- Phenylketonuria (PKU) is a genetic disorder that can lead to intellectual disability if untreated.
- Newborn screening programs are crucial for early detection and intervention.
- Ontario implemented a PKU screening program in 1966.
Purpose of the Study:
- To evaluate the effectiveness and incidence of phenylketonuria (PKU) in Ontario newborns.
- To assess the impact of early detection and treatment on developmental outcomes.
- To analyze the cost-effectiveness of the PKU screening program.
Main Methods:
- Analysis of data from Ontario's newborn screening program (1966-1971).
- Identification of infants with classical and atypical phenylketonuria (PKU).
- Tracking of treatment success and developmental outcomes, including intellectual disability.
Main Results:
- The program screened 94.5% of newborns, identifying 70 infants with PKU (47 classical, 23 atypical).
- Incidence rates were 1:16,700 for classical PKU and 1:34,000 for atypical PKU.
- 44 children treated in infancy showed successful outcomes, with only three developing retardation, two of whom were missed by screening.
Conclusions:
- Ontario's newborn screening for PKU is highly effective in identifying affected infants.
- Early detection and treatment of PKU prevent intellectual disability and improve long-term outcomes.
- The PKU screening program is cost-effective, preventing significant lifetime care costs for individuals with severe intellectual disability.
Abstract:
Ontario's program for PKU screening of newborn infants reached 94.5% of the newborn population from 1966 to 1971. There were 70 infants identified by the program, 47 of whom were classical cases and 23 atypical cases of phenylketonuria. The incidence was 1:16,700 live births for classical cases and 1:34,000 live births for atypical cases. Since the beginning of the program 44 children have been identified in infancy as having PKU and have been treated successfully. Retardation has become evident in only three infants, two of whom were missed by the screening program.The cost of identification and care of one child for five years is about $7000, much less than the $250,000 needed to provide lifetime institutional care for one severely retarded individual.